Evidence map›Paper›PMID 28560383›Full record

Trial reportInternational journal of oncology2017

Effects of genistein supplementation on genome‑wide DNA methylation and gene expression in patients with localized prostate cancer.

Birdal Bilir, Nitya V Sharma, Jeongseok Lee, Bato Hammarstrom, Aud Svindland, Omer Kucuk, Carlos S Moreno

Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 79 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Cancer chemoprevention: signaling pathways and strategic approaches.Signal transduction and targeted therapy · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Birdal BilirDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.
Nitya V SharmaDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.
Jeongseok LeeDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.
Bato HammarstromDepartment of Urology, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway.
Aud SvindlandDepartment of Clinical Medicine, University of Oslo, Oslo, Norway.
Omer KucukDepartment of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.
Carlos S MorenoDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.
Emory University · USOslo University Hospital · NOUniversity of Oslo · NO

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Ragini Reiney Kudchadkar · 2009 to 2026
$47.5M
NCI NIH HHS P30 CA138292
6 · The paper itself

Abstract

Epidemiological studies have shown that dietary compounds have significant effects on prostate carcinogenesis. Among dietary agents, genistein, the major isoflavone in soybean, is of particular interest because high consumption of soy products has been associated with a low incidence of prostate cancer, suggesting a preventive role of genistein in prostate cancer. In spite of numerous studies to understand the effects of genistein on prostate cancer, the mechanisms of action have not been fully elucidated. We investigated the differences in methylation and gene expression levels of prostate specimens from a clinical trial of genistein supplementation prior to prostatectomy using Illumina HumanMethylation450 and Illumina HumanHT-12 v4 Expression BeadChip Microarrays. The present study was a randomized, placebo-controlled, double-blind clinical trial on Norwegian patients who received 30 mg genistein or placebo capsules daily for 3-6 weeks before prostatectomy. Gene expression changes were validated by quantitative PCR (qPCR). Whole genome methylation and expression profiling identified differentially methylated sites and expressed genes between placebo and genistein groups. Differentially regulated genes were involved in developmental processes, stem cell markers, proliferation and transcriptional regulation. Enrichment analysis suggested overall reduction in MYC activity and increased PTEN activity in genistein-treated patients. These findings highlight the effects of genistein on global changes in gene expression in prostate cancer and its effects on molecular pathways involved in prostate tumorigenesis.

Indexed as

Dietary SupplementsGenome, HumanAgedAnticarcinogenic AgentsDNA MethylationDouble-Blind MethodFollow-Up StudiesGene Expression Regulation, NeoplasticGenisteinHumansMaleMiddle AgedPrognosisProstatectomyProstatic NeoplasmsAnticarcinogenic AgentsGenistein

Identifiers

PMID28560383
PMCPMC5467777
OpenAlexW2618696265

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.